GleamWall
中文EN

KPTI Karyopharm Therapeutics Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1503802 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.8%
TTM net income YoY-81.9%
TTM EPS YoY-2.7%
Revenue 3-yr CAGR0.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-56.2%
Net margin-153.3%
FCF margin—
EBITDA margin-56.1%

Returns

ROE—
ROA-207.9%
ROIC (approx.)—
Asset turnover1.36x

Leverage & solvency

Liabilities / assets396.6%
Debt / equity—
Current ratio0.79x
Interest coverage-1.67x

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio-147.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue$33.43M$35.07M$34.08M$44.04M$37.93M$30.02M$30.54M$38.78M
R&D expense$28.96M$33.80M$27.67M$30.54M$32.79M$34.62M$33.30M$36.13M
SG&A expense$25.92M$26.68M$22.77M$26.61M$28.48M$27.35M$27.19M$27.63M
Operating income-$22.53M-$26.76M-$17.84M-$15.22M-$24.39M-$33.26M-$31.28M-$26.28M
Interest expense$13.14M$12.55M$12.62M$11.01M$11.23M$10.99M$11.20M$11.38M
Pretax income-$67.02M-$22.39M-$102.27M-$33.09M-$37.21M-$23.43M-$30.89M-$32.04M
Income tax$0$1,000-$67,000$34,000$40,000$36,000-$109,000$28,000
Net income-$67.02M-$22.39M-$102.20M-$33.13M-$37.25M-$23.46M-$30.78M-$32.07M
EBITDA-$22.53M-$26.75M-$17.82M-$15.10M-$24.31M-$33.18M-$31.20M-$26.20M
EPS (basic)-2.32-1.02—-3.82-4.32-2.77—-3.85
EPS (diluted)-2.32-1.24—-3.82-4.32-2.77—-3.85
Weighted avg. shares (diluted)28,93824,715—8,6698,6208,470—8,336
Balance sheet
Cash & equivalents$54.98M$90.85M$60.54M$37.67M$38.73M$38.78M$62.81M$72.83M
Short-term investments$10.12M$0$3.20M$8.21M$12.97M$31.16M$46.24M$60.70M
Receivables$29.87M$23.36M$26.18M$31.88M$32.93M$35.24M$30.77M$31.78M
Inventory$3.99M$3.60M$4.04M$3.97M$4.99M$4.77M$4.74M$4.67M
Current assets$106.38M$126.33M$103.15M$89.75M$97.87M$120.24M$156.46M$184.75M
PP&E, net$94,000$91,000$104,000$122,000$244,000$322,000$400,000$495,000
Total assets$111.32M$131.42M$108.42M$96.23M$104.88M$127.71M$164.42M$189.48M
Current liabilities$134.23M$117.30M$92.06M$87.16M$99.22M$90.37M$92.26M$61.49M
Total liabilities$441.49M$397.06M$401.34M$365.49M$343.81M$333.60M$350.44M$349.12M
Shareholders' equity-$330.17M-$265.65M-$292.93M-$269.26M-$238.93M-$205.88M-$186.02M-$159.65M
Shares outstanding22.68M22.54M18.31M8.70M8.65M8.57M8.41M125.30M
Cash flow statement
Operating cash flow-$24.93M-$22.73M-$11.83M-$5.86M-$18.70M-$38.98M-$25.81M-$19.45M
Capital expenditure——$0$0$0$0-$53,000$0
Free cash flow——-$11.83M-$5.86M-$18.70M-$38.98M-$25.76M-$19.45M
Investing cash flow-$10.04M$3.20M$5.00M$4.80M$18.29M$15.29M$14.80M$7.47M
Financing cash flow-$898,000$49.80M$29.69M$0$356,000$0$680,000$0
Depreciation & amortization-$3,000$12,000$19,000$121,000$78,000$78,000$81,000$83,000
Stock-based compensation$1.93M$3.01M$3.90M$2.80M$3.78M$3.56M$3.86M$4.18M

Free plan shows the latest 8 periods; Pro shows all 58 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.